Same ingredient. Different products.

Semaglutide copies GLP-1, a gut hormone that sends signals about appetite and blood sugar.

A hormone is a signal made by the body; this medicine is an altered copy of that signal.

That explains the idea. It does not tell you which product fits your health.

The label is the official information for that particular medicine.

On September 26, 2026, semaglutide (Ozempic injection) had approval for blood sugar control in adults who have type 2 diabetes.

Type 2 diabetes is an illness that affects blood sugar. Weight loss is not an approved use on the Ozempic injection label.

Semaglutide (Wegovy) has a U.S. approval for weight management as of September 26, 2026.

For adults, its weight use covers obesity, meaning high body fat. It also covers excess weight when a related health problem is present.

In the label, obesity and excess weight are assessed using BMI, a measure based on height and weight.

The prescriber is the person deciding whether to order medicine for you. Ask them to explain where your health fits.

Both injection and tablet forms of Ozempic and Wegovy were approved as of September 26, 2026.

Semaglutide (Rybelsus) tablets treat diabetes. A notice checked September 26, 2026 says Ozempic tablets will replace them.

The notice gives no date for when Rybelsus will stop being supplied. It does not say that Rybelsus is already gone.

Ask the prescriber or pharmacy which tablet is available for your care.

Write down the form as well as the name. Then ask how the choice was made.